Niagen Bioscience Inc Dossier
Qualitative Analysis
Business overview
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly known as ChromaDex Corporation, is a global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. Headquartered in Los Angeles, California, the company specializes in developing and commercializing proprietary aging solutions, notably its flagship patented ingredient Niagen® (nicotinamide riboside, or NR). Niagen® is clinically proven to increase NAD+ levels efficiently and serves as the core ingredient powering the company's suite of brands. These include Tru Niagen®, its leading consumer oral supplement brand, and Niagen® Plus, its pharmaceutical-grade intravenous (Niagen IV) and injectable brand. The company operates a capital-light, outsourced consumer-health platform, managing ingredient sourcing and finished-goods production through qualified external manufacturing relationships.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launched a clinician-directed telehealth platform enabling eligible U.S. patients to access prescription-only, pharmaceutical-grade Niagen at-home subcutaneous injection kits.
Expected impact: Expands the clinical channel beyond in-person settings, introducing a direct-to-patient access model that leverages the growing consumer comfort with at-home injectables.
Established the Niagen Skincare Innovation Lab and introduced Niagen NanoCloud, a limited-release topical skincare product representing a new category extension for the company's NAD+ technology.
Expected impact: Enters the high-margin premium topical skincare market, diversifying the product portfolio beyond oral dietary supplements.
Sold the legacy ChromaDex Analytical Reference Standards and Services business to LGC Standards to fully exit non-core activities.
Expected impact: Streamlines operations, eliminates non-core G&A expenses, and focuses capital and talent entirely on NAD+ science, intellectual property, and commercial growth in the longevity industry.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms, consolidating the most critical intellectual property underlying the NR business. This transaction transitioned Niagen Bioscience from an exclusive licensee to the sole owner of the core body of patents underpinning the production, composition, and commercial use of NR.
Financial impact: Replaced prior joint ownership and licensing agreements, mutually terminating royalty obligations. Includes a $1.0 million payment for accrued royalties through 2024, annual payments of $500,000 and £35,000 from 2026 to 2038, and one-time payments of $1.5 million in 2035 and $2.0 million in 2038.
Strategic Partnerships
Marks the company's first cruise ship clinic partnership, expanding the Niagen Plus clinical footprint to over 80 Medi-Spa clinics onboard high-end cruise ships and introducing a premium channel targeting high-intent, on-vacation consumers.
Terms: Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, compounds and distributes the pharmaceutical-grade Niagen IV (500 mg) for the cruise ship clinics.
Secures exclusive global rights to develop and commercialize patented nicotinamide riboside (Niagen) as a potential pharmaceutical therapy for Parkinson's disease, utilizing clinical data from the Phase III NOPARK trial.
Terms: Underpins the establishment of a wholly owned subsidiary dedicated to regulated drug development in neurodegenerative diseases.